Effects of early parenteral iron combined erythropoietin in preterm infants

نویسندگان

  • Linxia Qiao
  • Qingya Tang
  • Wenying Zhu
  • Haiyan Zhang
  • Yuefang Zhu
  • Hua Wang
چکیده

BACKGROUD The aim of the study was to evaluate the effect of early parenteral iron supplementation combined erythropoietin for prevention of anemia in preterm infants. METHODS In total, 96 preterm infants were randomly assigned to 3 groups: a control group receiving standard parenteral nutrition (group 1: n = 31), an iron-supplemented group (group 2: IS, n = 33), and an iron-supplemented combined erythropoietin group (group 3: IS+EPO, n = 32). The primary objective was to assess hemoglobin (Hb) levels. The secondary objectives included assessment of red blood cell counts (RBC), mean cell volume (MCV), serum iron, ferritin, percentages of reticulocyte (RET), total iron binding capacity (TIBC) and oxidative stress, which was assessed by measuring plasma levels of malondialdehyde and superoxide dismutase at baseline and at 2 weeks. The blood routine indices including Hb, RBC, MCV, and percentages of RET were measured at corrected age of 1 and 3 months. RESULTS At 2 weeks of life, the percentages of reticulocyte in group 2 and group 3 were significantly higher than those in group 1 (2.1±0.4, 2.5±0.3, and 1.7±0.3, respectively, P < 0.001, P<0.001), whereas TIBC were significantly lower than those in group 1 (36.7±4.6, 36.0±4.7, and 41.6 ± 5.2 respectively, P = 0.011, P = 0.006). There were no significant differences in RBC counts, the levels of hemoglobin, ferritin, malondialdehyde, and superoxide dismutase among the 3 groups at 2weeks of life. RBC, Hb, MCV, body weight, body length, and head circumference at a corrected age of 1 month did not differ among 3 groups. At corrected age of 3months, more infants in the control group had abnormal Hb and MCV levels (Hb levels: 114.3 ± 21.3, 123.7 ± 31.6, and 125.1 ± 21.2, P = 0.021, P = 0.034, respectively; MCV: 74.1 ± 3.5, 78.3 ± 4.7 and 79.1 ± 5.2, P = 0.017, P = 0.012, respectively), whereas cases of oral iron, cases of breastfeeding, RBC, body weight, body length, and head circumference were not different among 3 groups. CONCLUSION Early parenteral iron supplementation combined erythropoietin in preterm infants improved the percentages of reticulocyte, decreased total iron binding capacity, and improved the Hb and MCV levels at 3 months of age. Early parenteral iron supplementations with EPO were beneficial for the preterm infants.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

The Effect of Early Subcutaneous Administration of Erythropoietin on Hematopoiesis and Weight Gain Velocity in Preterm Infants

Abstract Introduction Anemia in preterm infants is identified as hemoglobin lower than 7-10g/dl around 1-3 months after birth. The aim of this study was to evaluate the effect of early subcutaneous administration of erythropoietin on hematopoiesis and weight gain velocity in preterm infants. Materials and Methods The present study was clinical trial carried out on 42 preterm infants. Those ...

متن کامل

The effect of early recombinant erythropoietin and enteral iron supplementation on blood transfusion in preterm infants.

Premature infants<1500 g were randomly assigned to study and control groups. In the study group, 42 premature infants received recombinant human erythropoietin (r-Hu EPO) 750 U/kg per week subcutaneously from day 5 to 40 and enteral iron supplementation of 2 to 6 mg/kg/d beginning on day 14 provided that they were receiving at least 50% energy intake orally. In the control group, 51 infants rec...

متن کامل

Erythropoietin Concentrations and Neurodevelopmental Outcome in Preterm

OBJECTIVE.Erythropoietin therapy is effective in decreasing transfusions to varying degrees in preterm infants. Recent animal studies using erythropoietin doses to achieve serum concentrations 1000 mU/mL report neuroprotective effects. We evaluated the relationship between erythropoietin concentrations and neurodevelopmental outcome in extremely low birth weight infants. METHODS. Preterm infant...

متن کامل

Effects of early human recombinant erythropoietin therapy on the transfusion in healthy preterm infants.

OBJECTIVE Early recombinant erythropoietin therapy and iron therapy would decrease the need for red blood cells transfusions and prevents anemia of prematurity. METHODS Fifty-eight preterm infants in newborn services at Ghaem Medical Center randomly were assigned, among them 18 patients were excluded. A total of 40 preterm infants with gestational age 28-34 weeks, birth weight 1000-1750 g fol...

متن کامل

اثر اریتروپوئتین دردرمان آنمی نارسی

Recombinant human erythropoietin (Epo) is known to accelerate&nbsp;erythropoesis in preterm infants. This study was designed to assess the effect&nbsp;of Epo in treatment of anemia of prematurity . Preterm infants with Hct <30% when infant&rsquo;s age was between 2 to 3&nbsp;weeks or Hct<25% when infant&rsquo;s age was more than 3 weeks , were divided&nbsp;randomly in two groups, each group ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره 96  شماره 

صفحات  -

تاریخ انتشار 2017